L1-79
Core social deficits in Autism Spectrum Disorder (ASD)
Phase 2Active
Key Facts
Indication
Core social deficits in Autism Spectrum Disorder (ASD)
Phase
Phase 2
Status
Active
Company
About Yamo Pharmaceuticals
Yamo Pharmaceuticals is a private, pre-revenue biotech company founded in 2017, advancing L1-79 for Autism Spectrum Disorder (ASD). The therapy, which regulates catecholamine pathways in the central and autonomic nervous systems, recently concluded a Phase 2 study in July 2024, showing promising efficacy and a well-tolerated profile. The company is positioned to address a large, underserved market with no approved pharmacologic treatments for the core social symptoms of ASD. Success in future clinical development could establish Yamo as a leader in neurodevelopmental therapeutics.
View full company profile